Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghua Decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is primarily investigated for the treatment of nonalcoholic fatty liver disease (NAFLD), specifically in patients presenting with the 'turbid phlegm and internal resistance' syndrome. The decoction aims to reduce the risk of coronary artery disease in these patients by modulating metabolic markers such as Retinol-Binding Protein 4 (RBP4), Cyclophilin A (CyPA), and Insulin-like Growth Factor 1 (IGF-1), thereby improving insulin resistance and lipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qinghua decoction.